Stay on Top of Changes to COVID-19 Management
February 2022
Questions are popping up about changes with COVID-19 management...monoclonal antibodies (MAbs), remdesivir, etc.
It's partly because FDA has halted use of the MAbs bamlanivimab/etesevimab and casirivimab/imdevimab (Regen-COV)...since they don't work against the current Omicron variant.
Anticipate that the oral antiviral nirmatrelvir/ritonavir (Paxlovid) will be preferred for outpatients instead.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote